GGrantIndex
Sort

82,697 grants matching vaccine development

Bacteria and Host in TB Transmission

$1,612,367
David Alland · Rutgers Biomedical And Health Sciences · R01 · FY2025 · AI

SOUTH AFRICA MRC HIV PREVENTION TRIALS UNIT

$1,612,342
Medical Research Council Of South Africa · U01 · FY2001 · AI

Clinical Interventional Studies of HIV Reservoirs

$1,612,019
Frank Maldarelli · Division Of Basic Sciences - Nci · ZIA · FY2014 · CA

CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS)

$1,611,898
John Jay Treanor · University Of Rochester · N01 · FY2018 · AI

DEVELOPMENT OF A NEW, MORE EFFECTIVE LIVE-ATTENUATED INFLUENZA VACCINE: AN ESSENTIAL PLATFORM FOR FUTURE PANDEMIC PROTECTION

$1,611,885
University Of Rochester · · FY2017 · Department of the Army

Toxic substances in the environment

$1,611,169
Martyn T Smith · University Of California Berkeley · P42 · FY2023 · ES

DNA/MWA Immunogens, Cross-clade Immune Responses

$1,610,907
Emory University · P01 · FY2001 · AI

RFA-IP-22-004, Evaluating respiratory virus vaccine effectiveness in a large, diverse healthcare system

$1,610,715
Richard K Zimmerman · University Of Pittsburgh At Pittsburgh · U01 · FY2025 · IP

RFA-IP-22-004, Platform to Assess Influenza and COVID-19 Vaccine Effectiveness in Underserved Arizona Populations

$1,610,715
Vel Murugan · Arizona State University-Tempe Campus · U01 · FY2025 · IP

Novel inhibitors of the replication of poxviruses

$1,610,556
Katholieke Universiteit Leuven · UC1 · FY2004 · AI

Pre-Clinical Immunogenicity Testing of Chimp Adenovirus Vectors

$1,610,354
Hildegund C. J. Ertl · Wistar Institute · U19 · FY2009 · AI

Monoclonal Antibodies in Biodefense: Ebola Viruses

$1,610,165
Larry Zeitlin · Mapp Biopharmaceutical, Inc. · U01 · FY2009 · AI

University of Washington Arboviral Research Network (UWARN)

$1,609,959
Wesley C Van Voorhis · University Of Washington · U01 · FY2023 · AI

Seattle-Lausanne Clinical Trials Unit

$1,608,983
Margaret Juliana McElrath · Fred Hutchinson Cancer Research Center · UM1 · FY2021 · AI

AIDS CLINICAL TRIALS UNIT

$1,608,484
Stanford University · U01 · FY2004 · AI

Immune Function and Biodefense in Immunocrompromised Populations

$1,608,352
Kathleen Sullivan · Children'S Hosp Of Philadelphia · N01 · FY2010 · AI

Non-Human Primate Core

$1,607,891
Kathryn Foulds · National Institute Of Allergy And Infectious Diseases · ZIC · FY2023 · AI

Non-Human Primate Core

$1,607,891
Kathryn Foulds · National Institute Of Allergy And Infectious Diseases · ZIC · FY2022 · AI

Emory/Atlanta Center for AIDS Research

$1,607,431
James W. Curran · Emory University · P30 · FY2007 · AI

Cellular and Molecular Physiology of Bloodstream Malaria Parasites

$1,606,900
Sanjay A Desai · National Institute Of Allergy And Infectious Diseases · ZIA · FY2024 · AI

Combining germline-targeting, B cell immunofocusing and Env-Ab coevolution strategies to induce HIV Envelope V2-apex broadly neutralizing antibodies

$1,606,895
Raiees Ahmad Andrabi · University Of Pennsylvania · R33 · FY2025 · AI

Novel Chemical and Immunological Approaches to Influenza Therapy

$1,606,853
Michael B Oldstone · Scripps Research Institute, The · U01 · FY2007 · AI

Molecular Genetics Of Scrapie Pathogenesis

$1,606,708
Suzette Alise Priola · National Institute Of Allergy And Infectious Diseases · Z01 · FY2008 · AI

Evolution & Maintenance of Memory CD8 T Cells

$1,605,917
Katherine F Luzuriaga · Univ Of Massachusetts Med Sch Worcester · P01 · FY2007 · AI

PPG: SARS-CoV-host cell interactions and vaccine development

$1,605,748
Stanley Perlman · University Of Iowa · P01 · FY2013 · AI